Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.

Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intrad...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuhrie, S. R., Harris, R., Freeman, C. B., MacIver, J. E., Geary, C. G., Delamore, I. W., Tooth, J. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1980
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010236/
https://www.ncbi.nlm.nih.gov/pubmed/6992827
_version_ 1782136279138304000
author Zuhrie, S. R.
Harris, R.
Freeman, C. B.
MacIver, J. E.
Geary, C. G.
Delamore, I. W.
Tooth, J. A.
author_facet Zuhrie, S. R.
Harris, R.
Freeman, C. B.
MacIver, J. E.
Geary, C. G.
Delamore, I. W.
Tooth, J. A.
author_sort Zuhrie, S. R.
collection PubMed
description Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intradermal BCG plus allogeneic cells or to "no maintenance". Patients receiving immunotherapy had significantly longer remission (P = 0.039) and survival from remission (P = 0.044) as assessed by the log-rank test. The median duration of first remission for 21 patients receiving immunotherapy was 35.14 weeks, compared with 19.71 weeks for 20 patients on no maintenance, and the median survival from remission was doubled in patients receiving immunotherapy. The value of adequate consolidation chemotherapy is confirmed by the comparatively long first remissions in both groups compared with our previous trials, whilst avoidance of maintenance chemotherapy possibly allowed frequent second remissions and similar post-relapse survival in patients from both treatment arms.
format Text
id pubmed-2010236
institution National Center for Biotechnology Information
language English
publishDate 1980
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20102362009-09-10 Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia. Zuhrie, S. R. Harris, R. Freeman, C. B. MacIver, J. E. Geary, C. G. Delamore, I. W. Tooth, J. A. Br J Cancer Research Article Forty-one adult patients with acute myelogenous leukaemia entered remission induced by daunorubicin and cytosine arabinoside, and subsequently received 6 weeks' consolidation therapy with cyclophosphamide plus 6-thioguanine. They were then randomized to either immunotherapy consisting of intradermal BCG plus allogeneic cells or to "no maintenance". Patients receiving immunotherapy had significantly longer remission (P = 0.039) and survival from remission (P = 0.044) as assessed by the log-rank test. The median duration of first remission for 21 patients receiving immunotherapy was 35.14 weeks, compared with 19.71 weeks for 20 patients on no maintenance, and the median survival from remission was doubled in patients receiving immunotherapy. The value of adequate consolidation chemotherapy is confirmed by the comparatively long first remissions in both groups compared with our previous trials, whilst avoidance of maintenance chemotherapy possibly allowed frequent second remissions and similar post-relapse survival in patients from both treatment arms. Nature Publishing Group 1980-03 /pmc/articles/PMC2010236/ /pubmed/6992827 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Zuhrie, S. R.
Harris, R.
Freeman, C. B.
MacIver, J. E.
Geary, C. G.
Delamore, I. W.
Tooth, J. A.
Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title_full Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title_fullStr Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title_full_unstemmed Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title_short Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
title_sort immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010236/
https://www.ncbi.nlm.nih.gov/pubmed/6992827
work_keys_str_mv AT zuhriesr immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT harrisr immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT freemancb immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT maciverje immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT gearycg immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT delamoreiw immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia
AT toothja immunotherapyalonevsnomaintenancetreatmentinacutemyelogenousleukaemia

Ejemplares similares